Contribution of different mechanisms to pancreatic beta-cell hyper-secretion in non-obese diabetic (NOD) mice during pre-diabetes. 2011

Kuo Liang, and Wen Du, and Wenzhen Zhu, and Shuang Liu, and Yeqing Cui, and Haichen Sun, and Bin Luo, and Yanhong Xue, and Lu Yang, and Liangyi Chen, and Fei Li
Department of General Surgery, XuanWu Hospital, Capital Medical University, Beijing, 100053, PR China.

The development of insulin-dependent diabetes mellitus (IDDM) results from the selective destruction of pancreatic beta-cells. Both humans and spontaneous models of IDDM, such as NOD mice, have an extended pre-diabetic stage. Dynamic changes in beta-cell mass and function during pre-diabetes, such as insulin hyper-secretion, remain largely unknown. In this paper, we evaluated pre-diabetic female NOD mice at different ages (6, 10, and 14 weeks old) to illustrate alterations in beta-cell mass and function as disease progressed. We found an increase in beta-cell mass in 6-week-old NOD mice that may account for improved glucose tolerance in these mice. As NOD mice aged, beta-cell mass progressively reduced with increasing insulitis. In parallel, secretory ability of individual beta-cells was enhanced due to an increase in the size of slowly releasable pool (SRP) of vesicles. Moreover, expression of both SERCA2 and SERCA3 genes were progressively down-regulated, which facilitated depolarization-evoked secretion by prolonging Ca(2+) elevation upon glucose stimulation. In summary, we propose that different mechanisms contribute to the insulin hyper-secretion at different ages of pre-diabetic NOD mice, which may provide some new ideas concerning the progression and management of type I diabetes.

UI MeSH Term Description Entries
D007328 Insulin A 51-amino acid pancreatic hormone that plays a major role in the regulation of glucose metabolism, directly by suppressing endogenous glucose production (GLYCOGENOLYSIS; GLUCONEOGENESIS) and indirectly by suppressing GLUCAGON secretion and LIPOLYSIS. Native insulin is a globular protein comprised of a zinc-coordinated hexamer. Each insulin monomer containing two chains, A (21 residues) and B (30 residues), linked by two disulfide bonds. Insulin is used as a drug to control insulin-dependent diabetes mellitus (DIABETES MELLITUS, TYPE 1). Iletin,Insulin A Chain,Insulin B Chain,Insulin, Regular,Novolin,Sodium Insulin,Soluble Insulin,Chain, Insulin B,Insulin, Sodium,Insulin, Soluble,Regular Insulin
D003922 Diabetes Mellitus, Type 1 A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence. Diabetes Mellitus, Brittle,Diabetes Mellitus, Insulin-Dependent,Diabetes Mellitus, Juvenile-Onset,Diabetes Mellitus, Ketosis-Prone,Diabetes Mellitus, Sudden-Onset,Diabetes, Autoimmune,IDDM,Autoimmune Diabetes,Diabetes Mellitus, Insulin-Dependent, 1,Diabetes Mellitus, Type I,Insulin-Dependent Diabetes Mellitus 1,Juvenile-Onset Diabetes,Type 1 Diabetes,Type 1 Diabetes Mellitus,Brittle Diabetes Mellitus,Diabetes Mellitus, Insulin Dependent,Diabetes Mellitus, Juvenile Onset,Diabetes Mellitus, Ketosis Prone,Diabetes Mellitus, Sudden Onset,Diabetes, Juvenile-Onset,Diabetes, Type 1,Insulin Dependent Diabetes Mellitus 1,Insulin-Dependent Diabetes Mellitus,Juvenile Onset Diabetes,Juvenile-Onset Diabetes Mellitus,Ketosis-Prone Diabetes Mellitus,Sudden-Onset Diabetes Mellitus
D005260 Female Females
D005947 Glucose A primary source of energy for living organisms. It is naturally occurring and is found in fruits and other parts of plants in its free state. It is used therapeutically in fluid and nutrient replacement. Dextrose,Anhydrous Dextrose,D-Glucose,Glucose Monohydrate,Glucose, (DL)-Isomer,Glucose, (alpha-D)-Isomer,Glucose, (beta-D)-Isomer,D Glucose,Dextrose, Anhydrous,Monohydrate, Glucose
D005951 Glucose Tolerance Test A test to determine the ability of an individual to maintain HOMEOSTASIS of BLOOD GLUCOSE. It includes measuring blood glucose levels in a fasting state, and at prescribed intervals before and after oral glucose intake (75 or 100 g) or intravenous infusion (0.5 g/kg). Intravenous Glucose Tolerance,Intravenous Glucose Tolerance Test,OGTT,Oral Glucose Tolerance,Oral Glucose Tolerance Test,Glucose Tolerance Tests,Glucose Tolerance, Oral
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000078790 Insulin Secretion Production and release of insulin from PANCREATIC BETA CELLS that primarily occurs in response to elevated BLOOD GLUCOSE levels. Secretion, Insulin
D000375 Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time. Senescence,Aging, Biological,Biological Aging
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013549 Sweetening Agents Substances that sweeten food, beverages, medications, etc., such as sugar, saccharine or other low-calorie synthetic products. (From Random House Unabridged Dictionary, 2d ed) Artificial Sweeteners,Sugar Substitutes,Sweeteners,Agent, Sweetening,Agents, Sweetening,Artificial Sweetener,Substitute, Sugar,Substitutes, Sugar,Sugar Substitute,Sweetener,Sweetener, Artificial,Sweeteners, Artificial,Sweetening Agent

Related Publications

Kuo Liang, and Wen Du, and Wenzhen Zhu, and Shuang Liu, and Yeqing Cui, and Haichen Sun, and Bin Luo, and Yanhong Xue, and Lu Yang, and Liangyi Chen, and Fei Li
July 1984, Diabetologia,
Kuo Liang, and Wen Du, and Wenzhen Zhu, and Shuang Liu, and Yeqing Cui, and Haichen Sun, and Bin Luo, and Yanhong Xue, and Lu Yang, and Liangyi Chen, and Fei Li
July 1993, Metabolism: clinical and experimental,
Kuo Liang, and Wen Du, and Wenzhen Zhu, and Shuang Liu, and Yeqing Cui, and Haichen Sun, and Bin Luo, and Yanhong Xue, and Lu Yang, and Liangyi Chen, and Fei Li
May 1996, Regulatory peptides,
Kuo Liang, and Wen Du, and Wenzhen Zhu, and Shuang Liu, and Yeqing Cui, and Haichen Sun, and Bin Luo, and Yanhong Xue, and Lu Yang, and Liangyi Chen, and Fei Li
January 1985, Virchows Archiv. B, Cell pathology including molecular pathology,
Kuo Liang, and Wen Du, and Wenzhen Zhu, and Shuang Liu, and Yeqing Cui, and Haichen Sun, and Bin Luo, and Yanhong Xue, and Lu Yang, and Liangyi Chen, and Fei Li
December 1995, Journal of autoimmunity,
Kuo Liang, and Wen Du, and Wenzhen Zhu, and Shuang Liu, and Yeqing Cui, and Haichen Sun, and Bin Luo, and Yanhong Xue, and Lu Yang, and Liangyi Chen, and Fei Li
June 1982, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
Kuo Liang, and Wen Du, and Wenzhen Zhu, and Shuang Liu, and Yeqing Cui, and Haichen Sun, and Bin Luo, and Yanhong Xue, and Lu Yang, and Liangyi Chen, and Fei Li
July 1997, Diabetes research and clinical practice,
Kuo Liang, and Wen Du, and Wenzhen Zhu, and Shuang Liu, and Yeqing Cui, and Haichen Sun, and Bin Luo, and Yanhong Xue, and Lu Yang, and Liangyi Chen, and Fei Li
January 2008, Novartis Foundation symposium,
Kuo Liang, and Wen Du, and Wenzhen Zhu, and Shuang Liu, and Yeqing Cui, and Haichen Sun, and Bin Luo, and Yanhong Xue, and Lu Yang, and Liangyi Chen, and Fei Li
June 1985, Clinical and experimental immunology,
Kuo Liang, and Wen Du, and Wenzhen Zhu, and Shuang Liu, and Yeqing Cui, and Haichen Sun, and Bin Luo, and Yanhong Xue, and Lu Yang, and Liangyi Chen, and Fei Li
January 2000, Diabetes/metabolism research and reviews,
Copied contents to your clipboard!